Sanofi's hemophilia drug comes into focus as delays hit a key competitor

Results from a small study of hemophilia patients published in The New England Journal of Medicine suggest a drug being developed by the French pharmaceutical giant Sanofi could challenge market-leading treatments for the rare bleeding disorder.